Trusted Resource for Clinical Trials, Protocols & Progress
A database lock is the formal process of finalizing clinical trial data to prevent further modifications, ensuring that analyses and submissions are based on a fixed dataset. Timely database lock is critical for maintaining trial integrity, supporting accurate statistical analyses, and meeting regulatory submission timelines.
Click to read the full article.
Concomitant medications—defined as any drug or therapy taken by a subject in addition to the investigational product—play a crucial role in clinical trial safety assessments. Regulatory authorities require complete and accurate documentation of these medications because they can confound efficacy results, contribute to adverse events (AEs), or highlight prohibited drug interactions. Yet, documentation gaps in concomitant medication records remain one of the most common investigator site-level audit findings.
Click to read the full article.
Electronic Data Capture (EDC) systems are at the core of clinical trial data management. Validation of these systems ensures that data is collected, stored, and reported accurately in compliance with ICH GCP, FDA 21 CFR Part 11, and EMA Annex 11. When EDC systems are inadequately validated, trial data integrity is compromised, leading to recurring regulatory audit findings.
Click to read the full article.
Protocol deviations occur when trial conduct does not strictly follow the approved clinical trial protocol. Regulators, including the FDA, EMA, and MHRA, view deviations as a serious threat to both data integrity and patient safety. Even minor deviations, if recurring, can raise questions about the reliability of study outcomes and the adequacy of investigator oversight. As such, protocol deviations consistently appear in regulatory inspection reports and are among the most frequent findings at investigator sites.
Click to read the full article.
Clinical trial data must remain secure, reliable, and accessible throughout the study lifecycle. Regulatory authorities including the FDA, EMA, and MHRA emphasize the need for robust data backup and security systems to safeguard against data loss, corruption, or unauthorized access. Missing data backups or weak security protocols are frequently cited as major audit findings, as they jeopardize trial integrity and patient safety.
Click to read the full article.
Source Data Verification (SDV) is the process by which clinical monitors confirm that data entered into Case Report Forms (CRFs) or electronic data capture (EDC) systems accurately reflects original source documents, such as patient charts, laboratory reports, or diagnostic test results. SDV is a cornerstone of ICH GCP compliance because it ensures data integrity, reliability, and traceability. Failures in this area are considered high-risk audit findings since they undermine confidence in the trial results and pose potential patient safety concerns.
Click to read the full article.
Protecting patient confidentiality is one of the core ethical and regulatory requirements in clinical research. Clinical trial subjects volunteer their personal health information (PHI) with the expectation that their identities will remain private, as outlined in international guidance such as ICH GCP E6(R2), the U.S. Health Insurance Portability and Accountability Act (HIPAA), and the EU General Data Protection Regulation (GDPR). When confidentiality safeguards fail, it not only jeopardizes subject trust but also leads to major or critical audit findings during regulatory inspections.
Click to read the full article.
Remote monitoring has become an integral part of clinical trial oversight, particularly following the COVID-19 pandemic. Sponsors and CROs increasingly rely on electronic data systems, eCRFs, and virtual monitoring visits to reduce costs and enhance efficiency. However, regulators including the FDA, EMA, and MHRA have repeatedly cited data integrity issues as common audit findings in trials that rely heavily on remote monitoring.
Click to read the full article.
Sponsors hold ultimate responsibility for the conduct, integrity, and compliance of clinical trials. While investigator sites and CROs execute much of the operational work, sponsors remain accountable to regulators such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other authorities worldwide. Regulatory audits assess whether sponsors meet obligations under ICH GCP E6(R2) and local regulations, focusing on oversight, documentation, and systems for quality management.
Click to read the full article.
Electronic Case Report Forms (eCRFs) are the backbone of data capture in clinical trials. Every data point recorded reflects protocol adherence, from dosing schedules to visit windows. Audit trails in eCRFs capture who entered or changed data, when, and why. Regulators such as the FDA, EMA, and MHRA increasingly rely on these audit trails to detect protocol deviations during inspections.
Click to read the full article.
